Esophageal cancer mediastinal lymph node metastasis can be treated with radiation therapy, chemotherapy, targeted and immunotherapy.
Esophageal cancer mediastinal lymph node metastasis belongs to stage IV esophageal cancer. The overall five-year survival rate of esophageal cancer is about 20%.
The principle of esophageal cancer treatment is multidisciplinary comprehensive treatment. However, stage IV esophageal cancer is a contraindication to surgery, so radiation therapy and chemotherapy can be used for mediastinal lymph node metastasis of esophageal cancer.
Radiotherapy: esophageal cancer is a tumor sensitive to radiotherapy. Radiotherapy is mainly divided into preoperative radiotherapy, postoperative radiotherapy and radical radiotherapy, which is mostly applied to cervical esophageal cancer and upper thoracic esophageal cancer, and can also be used for those who have contraindications to surgery but can still tolerate radiotherapy.
Chemotherapy: Chemotherapy for esophageal cancer is divided into palliative chemotherapy, neoadjuvant chemotherapy and adjuvant chemotherapy. Chemotherapy can relieve symptoms and improve the quality of life of esophageal cancer patients. Depending on the situation, it can be combined with targeted and immunotherapy.
For esophageal cancer with mediastinal lymph node metastasis, it is recommended to consult doctor in time and choose reasonable treatment plan under doctor’s guidance, so as to improve the prognosis and prolong the survival period.